What the FDA labels say about taking them together
Digoxin and glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “Measure serum digoxin concentrations before initiating MAVYRET. Reduce digoxin concentrations by decreasing the dose by approximately 50% or by modifying the dosing frequency and continue monitoring.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.).
What does the digoxin label say about glecaprevir/pibrentasvir?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the glecaprevir/pibrentasvir label say about digoxin?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Digoxin; Effect on Concentration: ↑ digoxin; Clinical Comments: Measure serum digoxin concentrations before initiating MAVYRET. Reduce digoxin concentrations by decreasing the dose by approximately 50% or by modifying the dosing frequency and continue monitoring.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Glecaprevir/pibrentasvir | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $152.98 per tablet 100-40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once